Literature DB >> 10946777

Shorter waiting times for hepatitis C virus seropositive recipients of cadaveric renal allografts from hepatitis C virus seropositive donors.

A K Mandal1, E S Kraus, M Samaniego, R Rai, S L Humphreys, L E Ratner, W R Maley, J F Burdick.   

Abstract

INTRODUCTION: The purposes of this study were: 1) to analyze the early results of cadaveric renal transplantation from either hepatitis C virus seropositive (HCV+ ) or hepatitis C virus seronegative (HCV-) donors into HCV + recipients; and 2) to determine whether HCV+ patients with end-stage renal disease (ESRD) might benefit from receiving renal allografts from HCV + donors.
METHODS: From January 1997 to June 1999, 28 patients with ESRD and HCV infection underwent 29 cadaveric renal transplants. The data were reviewed retrospectively. Nineteen of the renal transplants were performed with allografts obtained from 15 HCV + donors and 10 with allografts obtained from 10 HCV- donors. The median follow-up was 16.2 months, with an average of 15.4+/-2 months.
RESULTS: Recipients of HCV + renal allografts had shorter waiting times for transplantation. On average, patients who received a kidney from HCV + donors were transplanted 9+/-3 months after being placed on the transplant list, compared to 29+/-3 months for patients who received a kidney from a HCV- donor. Shorter waiting times were noted in every blood type group. There were no significant differences in rejection episodes, infectious complications, renal function, liver function, graft survival, or patient survival.
CONCLUSIONS: The use of renal allografts from HCV + donors for HCV + recipients shortens the waiting time for these patients, with no short-term differences in renal and liver function, graft loss, or patient survival.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10946777     DOI: 10.1034/j.1399-0012.2000.14040602.x

Source DB:  PubMed          Journal:  Clin Transplant        ISSN: 0902-0063            Impact factor:   2.863


  10 in total

1.  PHS guideline for reducing human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission through organ transplantation.

Authors:  Debbie L Seem; Ingi Lee; Craig A Umscheid; Matthew J Kuehnert
Journal:  Public Health Rep       Date:  2013-07       Impact factor: 2.792

2.  Impact of Willingness to Accept Hepatitis C Seropositive Kidneys Among Hepatitis C RNA-Positive Waitlisted Patients.

Authors:  Junichiro Sageshima; Christoph Troppmann; John P McVicar; Chandrasekar Santhanakrishnan; Angelo M de Mattos; Richard V Perez
Journal:  Transplantation       Date:  2018-07       Impact factor: 4.939

Review 3.  Kidney transplantation from donors with hepatitis C infection.

Authors:  Massimiliano Veroux; Daniela Corona; Nunziata Sinagra; Alessia Giaquinta; Domenico Zerbo; Burcin Ekser; Giuseppe Giuffrida; Pietro Caglià; Riccardo Gula; Vincenzo Ardita; Pierfrancesco Veroux
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

4.  KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2018-09-19

Review 5.  Hepatic disorders in chronic kidney disease.

Authors:  Fabrizio Fabrizi; Piergiorgio Messa; Carlo Basile; Paul Martin
Journal:  Nat Rev Nephrol       Date:  2010-04-13       Impact factor: 28.314

6.  Estimating the potential pool of HIV-infected deceased organ donors in the United States.

Authors:  B J Boyarsky; E C Hall; A L Singer; R A Montgomery; K A Gebo; D L Segev
Journal:  Am J Transplant       Date:  2011-03-28       Impact factor: 8.086

7.  A decade of experience with renal transplantation in African-Americans.

Authors:  Clarence E Foster; Benjamin Philosophe; Eugene J Schweitzer; John O Colonna; Alan C Farney; Bruce Jarrell; Leslie Anderson; Stephen T Bartlett
Journal:  Ann Surg       Date:  2002-12       Impact factor: 12.969

Review 8.  Hepatitis C and its impact on renal transplantation.

Authors:  Jose M Morales; Fabrizio Fabrizi
Journal:  Nat Rev Nephrol       Date:  2015-02-03       Impact factor: 28.314

9.  Utilization of HCV Viremic Kidneys with Genotyping/Subtyping-Free Sofosbuvir/Velpatasvir Treatment Strategy: Experience from China.

Authors:  Hedong Zhang; Qiuhao Liu; Shanbiao Hu; Mingda Zhong; Fenghua Peng; Yong Guo; Chunhua Fang; Manhua Nie; Liang Tan; Helong Dai; Xubiao Xie; Longkai Peng; Gongbin Lan
Journal:  Biomed Res Int       Date:  2022-07-30       Impact factor: 3.246

10.  Underutilization of Hepatitis C Virus Seropositive Donor Kidneys in the United States in the Current Opioid Epidemic and Direct-Acting Antiviral Era.

Authors:  Andrew A Li; George Cholankeril; Xingxing S Cheng; Jane C Tan; Donghee Kim; Alice E Toll; Satheesh Nair; Aijaz Ahmed
Journal:  Diseases       Date:  2018-07-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.